L ymphedema is a condition in which excessive fluid and protein accumulate in the interstitial spaces (Rockson, 200 I) . It occurs when the lymph atic system cannot accept fluid from the interstitium, cannot transport lymph into the circulatory system , or both (Browse, Burnand, & Mortimer, 2003) . Lymphedema can arise from primary (idiopathic) or secondary (acquired) conditions. Primary lymphedema occurs in about I of every 10,000 individuals (Townsend, Beauchamp, Evers, & Mattox, 2001 ). Secondary lymphedema occurs as a result of trauma to the lymphatic system. The leading cause of secondary lymphedema in the United States ~ Despite advances in laboratory science to identify and understand the origins of primary lymphedema an d modifications of cancer treatment to dec rease secondary lymphedema, new lymphedema cases continue to be identified.
~ Lymphedema requires burdensome, lifelong self-care to stimulate lymphatic drainage.
~Improve d at-home treat ment methods are needed.
~Part icipan ts reported sati sfaction an d perceived benefit from using a new home-based lymphedema treatment system that promotes lymphatic drainage.
is cancer treatment. Lymphedema rates in patients treated for cancer vary based on cancer type, site, severity, and treatment , as well as length of time post-tre atment and criteri a used for lymphedema diagnosis (Cormier, Davidson, Xing, Evans, & Armer, 2006; Starritt et al., 2004 upper-extremity lymphedema in women after breast cancer treatment is estimated to be 20%-36 % at 2 years posttreatment, increasing to 30%-45% at 15 or more years posttreatment (Erickson, Pearson, Ganz, Adams , & Kahn , 200 I) .
Even by the lowest estimates, lymphedema affects hundreds of thousands of people in the United States (American Cancer Society, 2006) .
Early diagnosis and treatment of lymphedema improve patient outcomes (Ramos, O'Donnell, & Kni g ht, 1999 ) .
Untreated lymphedema or lymphedema unresponsive to treatment progresses through three stages of increasing severity (Pain & Purushotham, 2000) . In stage I, limb elevation temporarily relieves swelling but does not change the underlying lymphatic dysfunction. In stage II, elevation does not relieve swelling, the limb can become firmer and not pit with pressure, and skin changes may be noted. In stage III, enlargement of tissues causes severe swelling, thick skin, and large skin folds. Fibrosis occurs in stages II and III. Despite advances in identifying and understanding the origins of primary lymphedema and improved cancer treatments designed to decrease the incidence of secondary lymphedema, new lymphedema cases continue to occur and be identified for many reasons. First, lymphatic research is a young investigative field; it will be many years before preventive or curative interventions are available. Second, improvements in cancer detection and treatment have increased the absolute numbers of cancer survivors, leaving more at risk for developing lymphedema. Third, because cancer survivors are living longer, they also are aging, and because lymphedema occurs more frequently in older cancer survivors, more people will be at risk for developing lymphedema (Armer & Fu, 2005) . Fourth, changes in cancer treatment have reduced but not eliminated lymphedema as a treatment side effect (Fleissig et al., 2006; Morrell et al., 2005) . Fifth, the activities of organizations such as the Lymphatic Research Foundation and the National Lymphedema Network have increased lymphedema awareness and accentuated the importance of diagnosis and treatment. Finally, certain populations that are increasing in number in the United States may be at greater risk of developing lymphedema. A study of low-income survivors of breast cancer found an overall lymphedema rate of 63% in a study population of breas t cancer survivors, with rates of 75 % among Latinos and 77% among African American women (Eversley et al., 2005) .
Literature Review
Lymphedema is a chronic condition for which treatment is available, but no cure exists. It is associated with impairment of function, significant psychosocial morbidity, and decreased quality of life (QOL). Physical sequelae can include impaired mobility, decreased range of motion and physical function , pain, compromised immune function, and increased incidence of acute inflammatory episodes and infection (including lifethreatening systemic infections such as erysipelas or cellulitis, sometimes requiring hospitalization) (American Cancer Society, 2006; Ehrlich, Vinje-Harrewijn , & McMahon, 2005; Morgan, Franks, & Moffatt, 2005) . Psychological sequelae include increased anxiety (especially social anxiety), depression, phobias, social withdrawal, sexual dysfunction, negative body image, loss of confidence in the body, lowered self-esteem, anger, and frustration (Augustin, Bross, Foldi, Vanscheidt, & Zschocke, 2005; Johansson et al., 2003; McMahon, 2005; McWayne & Heiney, 2005; Ridner, 2005; Rowl and & Yancik, 2006; Williams, Moffatt, & Franks, 2004) . Lymphedema is associated with decreased QOL (Armer & Heckathorn, 2005; Kornblith et al., 2003 ; Ridner) . The decreased QOL can be unrelated to the objectively measured volume of the lymphedematous limb (Morgan et al.; Starritt et al., 2004) .
Current lymphedema treatments are less than optimal, and improved home-based treatments are needed. Notably, many patients who comply with all prescribed treatment recommendations experience acute exacerbations of swelling and infections. Lymphedema treatment requires the intervention of specially trained healthcare professionals. The current gold standard of treatment is complete decongestive therapy (CDT), which includes manual lymphatic drainage (MLD), compression garments and bandaging, and meticulous skin care (Petrek, Pressm an, & Smith, 2000) . However, other treatments are used at times, such as pneumatic compression devices, ultrasound, and lasers (Balzarini et al., 1993; Piller & Thelander, 1998; Richmand, O'Donnell, & Zelikovski, 1985) . Liposuction and macrosurgical or microsurgical techniques occasionally are undertaken when noninvasive treatment fails (Johansson, Albertsson , Ingvar, & Ekdahl, 1999; Johansson, Lie, Ekdahl, & Lindfelt, 1998) . The longterm benefits of invasive procedures are unknown, and any improvements in limb size are maintained only with compression garments.
Regardless of the type of volume-reduction treatment, burdensome lifelong se lf-care that includes compression, self-administered MLD, and skin care is required to maintain volume reduction after CDT or to achieve additional volume reduction. The physical demands of self-MLD and application of compression garments may be difficult for patients with limited arm mobility because of the effects of cancer treatment or lymphedema itself and for those with comorbid conditions such as obesity or arthritis. Self-care is emotionally distressing because the activities require more than an hour every day. Also, many third-party payers do not cover repeated CDT and MLD sessions, compression garments, or other supplies; therefore, fin ancial problems often arise. In addition, the social and psychological impact of weming visible compression gm·ments or the visual effects of lymphedema may be traumatic.
Study Rationale
Reducing treatment burden may improve self-care and produce better patient outcomes (Boris, Weindorf, & Lasinkski, 1997) . Various types of garments and compression pumps have been developed in attempts to reduce patient burden and improve outcomes. Older-generation compression pumps can present an unacceptable risk of potential damage to the lymphatic system and, in some cases, when used to treat lower-limb lymphedema, can contribute to the development of genital edema (Boris et a!., 1998; Cheville et a!., 2003) .
Newer devices, when used with appropriate training and education, are believed to be safer than their older counterparts because they are designed to follow the physiologic principles of MLD. The segmented, programmable Flexitouch® (Tactile Systems Technology, Inc.) system (see Figure 1) is one example of a new-generation device. Unlike limb-i solating compression devices that compress only the limb itself, the Flexitouch system applies light, dynamic, vari able pressure to the affected limb and beyond the limb junction to the trunk ONCOLOGY NURSING FORUM -VOL 35, NO 4, 2008 Figure 1. Flexitouch® System using multichambered, inflatable, and stretchable fabric garments. The garments have narrow chambers, ranging from 3.8-4.4 em wide, which simulate the work-and-release action of a therapist's hand. The average applied pressure is mild, in contrast to the static higher pressures associated with traditional compression pumps (Mayrovitz, 2007) . Results from a small, prospective, randomized, crossover pilot study (N = 10) comparing the Flexitouch system to self-administered MLD revealed a statistically sig nific ant difference (p = 0.002) in arm volume reduction with the Flexitouch system (Wilburn, Wilburn, & Rockson, 2006) . However, adherence to treatment protocols, satisfaction with the device, and response to at-home treatment have yet to be studied. Thus, the purpose of this quasi-experimental pre-/post-test study was to evaluate treatment protocol adherence, satisfaction, perceived effectiveness (maintaining limb size or achieving further reduction), and perceived physical and emotional responses to treatment of home-based individuals using the Flexitouch system. Specifically, comparison of responses was made between two patient groups most likely to use the device: individuals with primary, noncancer-related lymphedema and those with cancer-related secondary lymphedema. Findings from such comparisons can be useful in determining whether the previously tested protocol (Wilburn et a!.) is acceptable and perceived as beneficial to patients regardless of lymphedema cause or duration. Specific research questions included the following.
• Does a difference ex ist in the level of self-reported adherence with the recommended treatment protocol between participants with cancer-related lymphedema and those with lymphedema from noncancer causes? • Is adherence to the recommended treatment protocol associated with sociodemographic variables, lymphedema duration, lymphedema severity, or infection frequency? • Does a difference exist in stated satisfaction with the device between participants with cancer-related lymphedema and those with lymphedema from noncancer causes? • Does a difference exist in perceived effectiveness of the device (limb volume reduction) between participants with cancer-related lymphedema and those with lymphedema from noncancer causes?
• Does a difference exist in perceived impact of the device on physical and emotional well-being between participants with cancer-related lymphedema and those with lymphedema from noncancer causes? • What impact does use of the Flexitouch system have on at-home lymphedema self-care routines?
Methods

Setting and Sample
All individuals in the United States whose independent, private healthcare providers prescribed the Flexitouch system and whose treatment was initiated from March I, 2004 , to May 10, 2006 , were invited to participate in the study. Prescribing physicians were not interviewed about their reasons for prescribing the system, nor had the manufacturer asked them to prescribe the system. Participants purchased the system from the manufacturer either with insurance coverage or personal fu nds. For insurance to cover the Flexitouch system, patients typically must fail other methods of lymphedema treatment, such as compression garments, bandaging, exercise, and elevation, and be unable to use nonsegmented or nonprogrammable pumps. The sample consisted of communitydwelling individuals living in the continental United States or Alaska with lymphedema in one or more limbs.
Procedures
Participants gave consent for use of data collected during the study. Institutional review board approval was obtained from Vanderbilt University for analysis of a de-identified data set. Participants completed a pretherapy survey before initiating use of the Flexitouch system. Trained Flexitouch instructors provided approximately one hour of in-home education before system use. Participants were instructed in proper device usage , methods for donning and doffing the garments, and the therapy protocol. Specifically, participants were instructed to remove all restrictive clothing and jewelry before use, not eat immediately before therapy, lie flat with the limb slightly elevated , wrap garments snugly to ensure good skin contact, not in terrupt therapy sessions, complete the entire one-hour treatment, and follow additional therapistand physician-prescribed care including but not limited to nocturnal bandaging, compression garments, exercises, and skin care. The therapeutic protocol directed the participants to use the device for one hour twice per day for each affected area for the first month, then for one hour once per day thereafter as maintenance for each affected area. Participants completed a post-therapy survey after the first month of use.
A pretherapy questionnaire was sent to 286 individuals when or before they received the device; 241 returned the pretherapy survey and were sent a post-therapy questionnaire. To encourage participants to return the post-therapy survey, a research assistant called users who had not returned the questionnaire within two months of receiving the device. During the phone call, participants were encouraged to return the survey and offered the option of completing the survey over the phone. To eliminate data collection bias, the research assistant was not employed by the Flexitouch system manufacturer, had no previous contact with participants, and directly read from the survey when asking questions. Participants who received phone calls were asked, "Is there anything else you would like to add?" after the survey was completed.
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Instruments
Demographic information, age, and gender questions were included in the pretherapy survey. Participants self-reported disease and treatment information. The Short-Form Health Survey (SF -12) (Gandhi eta!. , 200 I; Ware, Kosinski , & Keller, 1996) was used to measure physical and mental aspects of QOL. The survey consists of 12 items measured on five-point scales and has eight subscales : general health, physical functioning, role physical, bodily pain, mental health, vitality, social functioning, and role emotional. Global physical and mental health scores can be calculated using the subscale scores. Test-retest intraclass correlations of 0.75 for the physical scale and 0.71 for the mental scale have been documented (Hurst , Ruta, & Kind, 1998) . The SF-12 has demonstrated discriminate validity when used with individuals with and without arm lymphedema (p < 0.01) (Paskett, Naughton, McCoy, Case, & Abbott , 2007) . A typical item is, "During the past four weeks, how much did pain interfere with your normal work including both work outside the home and housework?" (Ware, Kosinski, Turner-Bowker, & Gandek, 2005, p. 249) . Items from the SF-12 were modified on the post-therapy survey (e .g., "Since using the Flexitouch system, how much did pain interfere with your normal work including both work outside the home and housework?") to reinforce consideration of use of the Flexitouch system during responses.
Analysis
Statistical data analysis was conducted with SAS® (version 9.1. 
and variability (standard deviations and interquartile ranges) were used to describe the distributions. Because some of the distributions of values for the SF-12 scores were not distributed normally (skewed), nonparametric statistical methods (e.g., Spearman rank correlations, Wilcoxon signed-ranks tests for paired data) were used in conjunction with the parametric statistical methods (e.g., Pearson correlations, repeated-measures analysis of variance with difference contrasts) to assess the reliability of statistical conclusions. In all cases, conclusions based on nonparametric and parametric tests were in agreement. However, because of the skewed nature of the distributions of the SF-12 scores, bias-corrected bootstrapped 95 % confidence intervals were calculated. Study group comparisons of nominal categories were conducted using chi-square tests of independence; comparisons of ordered categories (e.g., adherence, satisfaction) used Mann-Whitney tests. Spearman rank correlations were used to measure the degree of association between ordinal variables. An alpha level of 0.05 was used for establishing statistical significance, and all tests were two tailed.
Results
Sample Characteristics
Of the 241 participants who returned the pretherapy survey and received devices, 155 (64%) completed information required for the analyses reported here. For inclusion, participants were required to indicate the cause of their lymphedema and return a follow-up, post-therapy survey during the maintenance phase of the protocol. The time between the pretherapy and post-therapy surveys averaged approximately seven months (range= 1-22 months). Sixty percent of the participants completed the study in six months or less and 85% completed it within a year. Pretherapy characteristics of the participants who completed the study and those who did not are summarized in Tables 1 and 2 . Those returning the post-therapy survey tended to be younger, had longer durations of infections, and reported higher baseline physical and mental health characteristics (p < 0.05).
Characteristics of the study participants with lymphedema secondary to cancer and those with lymphedema originating from some other source are summarized in Table 3 . Relative to the participants with lymphedema from other sources, a higher percentage of participants in the cancer group were female (97 % versus 71 %, p < 0.00 I), were older (p = 0.007), reported less severe lymphedema (p = 0.001), and reported less time between lymphedema cause and lymphedema diagnosis (p = 0.040).
Adherence by Group
The prescribed usage protocol of the Flexitouch system at the time the participants completed the post-therapy survey was once per day. Statistically significant differences were found in the patterns of adherence to the prescribed protocol between the types of lymphedema groups (p = 0.022). Among participants with noncancer-re1ated lymphedema, approximately 56% reported following the prescribed maintenance protocol of one time per day, with 7% reporting use more tha n once per day. Comparable percentages among the participants with cancer-related lymphedema were 32% following the prescribed protocol, 21 % more than once per day. A total of 47 % of the participants from the cancer group reported use below prescribed protocol or not at all. Of those, 39% reported use of more than once per week and 4 % reported no use. On the other hand, a total of 37 % of the participants with lymphedema not secondary to cancer reported lower than prescribed use; 27 % of them were using the device more than once per week and 7% were not using it at all.
Variables Influencing Adherence
No statistically significant association was found between reported use patterns and age group, gender, lymphedema severity, or time since diagnosis. In addition, no statistically significant association was found between reported use patterns and limb volume change. No statistically significant correlations were found between device use and infection frequency in the affected limb or interference with daily activities as a result of infections, perhaps related to the low incidence of infections in the study sample.
Satisfaction
Ninety percent of the study participants reported that they were satisfied with the Flexitouch system. Of them, more than 65 % reported that they were extremely satisfied. No statistically significant differences were found in reported satisfaction with the device between the groups with lymphedema related to cancer or from some other cause, among the age groups, or by gender. However, those who reported that they used the devise as prescribed reported statistically significant higher levels of satisfaction (p = 0.008), a pattern repeated in both lymphedema groups. All of the 7% of study participants who said they were dissatisfied with the device were using it less than the prescribed protocol or not at all.
Perceived Effectiveness
No statistically significant difference between the lymphedema groups was found in perceived effectiveness as measured by self-reported limb volume change. Positive limb volume outcome was defined as a participant perceiving that limb volume had been maintained or reduced wi th device use. Ninety-five percent of participants reported a self-perceived positive limb volume outcome. Of them, 42% reported selfperceived limb volume decreases as much as 20%, and an addi tional 20% reported decreases of less than 20%.
Physical and Emotional Health
Tables 4 and 5 provide summaries of the physical and emotional health assessments prior to and after use of the Flexitouch system. Clinically and statistically significant improvements occurred in all areas of perceived physical and emotional health (p ~ 0.006). Improvements were observed over time regardless of whether lymphedema was related to cancer.
Self-Care Impact
Figure 2 summarizes use patterns of various treatment protocols other than the Flexitouch system (e.g., bandaging, garments, self-and clinician-administered MLD) and changes in patterns. Garments were the most frequently used additional treatment before use of the Flexitouch system (76 %) and at follow-up (69% ). A statistically significant drop occurred in the use of clinician-administered MLD from 60% before using the device to 13% at follow-up (p < 0.001). Statistically ONCOLOGY NURSING FORUM -VOL 35, NO 4, 2008 significant decreases in the use of bandaging (p < 0.00 I) and self-MLD (p = 0.003) also were noted. Participants with cancer-related lymphedema used garments more than those with lymphedema from other causes before receiving the system (82% versus 68 %, p = 0.046); however, that difference disappeared at follow-up (71 % versus 66% ). No other statistically significant differences were found between self-reports of the use of bandaging, garments, or self-or clinician-administered MLD by the lymphedema groups at pre-or post-therapy, nor were any statistically significant differences found in changes in use patterns between the groups. In general, use of those other types of treatments decreased. No statistically significant associations between the reported uses of other treatments and the extent of use of the Flexitouch system were detected at follow-up.
Discussion
This study compared questionnaire data from individuals with cancer-related lymphedema and those with noncancerrelated lymphedema before and after adding the Flexitouch system to their regimens of lymphedema self-care. Adherence to prescribed, at-home self-care has been identified as the most important factor in treating lymphedema; thus, nonadherence to prescribed treatment represents a banier to improving outcomes (Boris et al., 1997) . Almost half of patients with chronic disease have problems following their treatment regimens (Dunbar-Jacob et al., 2000) , and based upon the current findings, those with lymphedema have simi lar difficulties. In this study, participants with noncancer-related lymphedema demonstrated greater treatment adherence than their cancerrelated lymphedema counterparts. A possible explanation for the difference is that because individuals with noncancerrelated lymphedema had lymphedema that was more severe and longer in duration, they were more motivated to adhere to the recommended protocol in hopes of achieving a good outcome (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Kralik, Koch, Price, & Howard, 2004) . The lack of a statistically significant difference in perceived limb volume change among the groups of participants using the device with similar frequencies suggests that primary and secondary lymphedema may respond similarly to the Flexitouch system.
Both participant groups were satisfied with the device and perceived it as beneficial. The high level of satisfaction across groups (90%) may reflect the participants' acceptance of the device and a willingness to integrate it into their treatment regimens.
The frequency of use was not significantly correlated with perceived limb volume change. This may reflect participants' understanding that maintaining limb size and achieving volume reduction are acceptable outcomes ofFlexitouch system use. Also, perhaps certain participants perceived simil ar results using the system less frequently than others. A previous pilot study of the treatment device (Wilburn et al., 2006) , using a validated measure of limb volume carried out by trained medical personnel , reported findings of improvement similar to those reported by study participants. Therefore, further study evaluating whether a correlation exists between objective and perceived limb volume change may be of value.
Both groups experienced significant improvements in all areas of perceived physical and emotional health between the pretherapy and post-therapy assessments. The findings suggest that, regardless of lymphedema cause, the Flexitouch system may have a positive effect on the QOL of those us- '"Bodily Pain" Short-Form Health Survey scale was renamed to indicate that a higher score (less interference from pain) is a more positive assessment.
Cl-95% confidence interval; SEM-standard error of the mean ing it. The general trend in dec lining use of other types of lymphedema self-care treatment was expected because the Flexitouch system promotes acute lymphatic drainage, as do self-and clinician-administered MLD and bandaging. The Flexitouch system may reduce self-care burden as well as patient and insurance expenses for clinician-administered MLD sessions. The slight decrease in wearing of garments raises a possible concern that participants may have discontinued that component of self-care despite receiving instructions to continue to use such garments as prescribed.
limitations
Findings should be considered in relation to the study's limitations. First, post-therapy questionnaires were obtained from only 64% of participants. Data suggest that despite eff orts to improve response rates from all participants, those responding were younger, had better global physical and psychological health scores, and had more problems with infections than those who did not respond. Thus, a possible response bias occurred. However, respondents' written and verbal comments included criticisms as well as prai se, suggesting that respondents were willing to voice dissatisfac ti on. Second, use of a convenience sample of patients with lymphedema whose healthcare professionals requested the Flexitouch system limits the generalizability of findings. Third, information about volume improvement in the affected limb(s) was self-reported . Thus, only the patients' perceptions of change were provided; whether actual physical improvements of the limb(s) occurred is unknown . Fourth, the absence of a pure control group raises the possibility that the positive findings may reflect a placebo response. Despite the limitations, the study obtained valuable information.
Implications Nursing Practice
Nurses who see patients with lymphedema always should ask what self-care practices patients are using to manage their lymphedema and how they perceive their self-care activities are affecting their lymphedema and their lives. As the Flexitouch system gains broader use, oncology nurses are likely to see patients who are using the system. Because adherence with prescribed protocols may vary, nurses should ask patients using the system about the prescribed frequency and duration of treatment sessions and actual patient practice. They also should assess patients' use of other necessary self-care treatments, particularly garments and compression sleeves. Patients should be encouraged to follow all prescribed protocols. If they are confused about what self-care regimens they should follow, nurses may facilitate communication between the lymphedema treatment team and patients for clarification.
Future Research
Findings fro m this study suggest that, subj ectively, most individuals with limb lymphedema perceive the Flexitouch system to be beneficial. Randomized clinical trials comparing limb volume change in individuals using the Flexitouch system to those using standard MLD treatment, limb-isolating pneumatic compression devices, or standard MLD used in conjunction with the Flexitouch system or limb-isolating pneumatic compression devices would provide valuable information about the objective clinical benefit of the system.
Longitudinal studies comparing the cost-effectiveness of the device in patients using self-MLD to those using the device also are indicated . Such studies should include device cost; the number, duration , and severity of infections; cost of treating infections; cost for professional MLD or CDT required to maintain or regain limb volume reduction; and other expenses such as compression bandages or garments.
Conclusions
Surveys of therapy satisfaction are important outcome indicators that can be used to determine which variables are associated with treatment adherence and satisfaction and to guide further patient-specific protocol development. Results from the study suggest that patients using the Flexitouch system are satisfied with the system and perceive it as beneficial in managing their lymphedema.
